Investor measurement

How does an investor measure the modified duration of linkers It sounds like a straightforward question and there is an easy answer, but it is sadly not the answer that people generally want. The easy answer is that a linker s modified duration is the (normalised) first derivative of price with respect to real yield, just as a conventional bond s modified duration is that with respect to nominal yield. This answer is a flippant one, because what people really want to know is some empirical rule about the sensitivity of a linker s price with respect to nominal yields, either for hedging purposes or in order to calculate aggregate duration statistics for portfolios holding both nominal and real bonds. 

Energy conseiwation typically involves making an investment that results in lower energy running costs. An investor (or policymaker) is often confronted with a list of possible conseiwation measures. The investor needs a way to rank the measures and then... 

Using a 260/wafer sales price for epitaxial silicon wafers and the United States MACRS tax-basis depreciation schedule, the investor s rate of return (IRR) is 18.3%. In addition, the return on investment (ROI) is 25.3%. These measures increase significantly with small changes in sales price for example, at 273/wafer, the IRR is 29.9%. Note that the economic analysis is somewhat shielded from variations in the price of epitaxial wafers because it is strongly linked to the price of the incoming polished wafers. In other words, the key metric of interest is the value added to the wafer by the epitaxial film deposition. 

The central issue in any stock offering is price. In traditional, profitable companies price is usually measured as a price/earnings ratio. Since biotech companies rarely are profitable, price is evaluated using the capitalized value of the outstanding stock, i.e., price per share times the total number of shares, compared to other companies at similar stages of development with comparable upside potential. This "market cap" number (either private or public) is what sophisticated biotech investors look to in measuring whether an offering price is fair. Two measures used are postmoney and premoney values. 

Postmoney value is the market cap after the funding is complete and is what new investors focus on. Postmoney value is measured against other deals and the likely step-up in value prior to the next funding evenf. As the biotech market heats up or cools down, comparable values rise and fall. During the venture capital stage, investors try to estimate when the company can do an IPO (their exit strategy) and at what premoney value, and based on this estimate, coupled with their target rate of refum, they discount back to what would be a reasonable private postmoney value. 

Such measures would improve the opportunities for investors in the natural gas sector, and restructure the gas market and also promote the direct private participation. However, in-depth analytical skills, management and administrative capacity will be needed in order to operate the companies, and to resolve problems such as non-payment and administrative interference in commercial activities. 

Second, when the financial sponsor exits the business, the joint financial success is equally measurable for the private equity investors and the management team sharing the equity participation. This is important, as it demonstrates fairness to both those who have worked hard on the financial sponsors side and those who have worked hard as responsible managers of LBOs. 

Return on equity, also known as return on investment (ROI), is a measure of how well the company can make profits from funds provided by owners or investors. High ROE levels are desirable because investors— similar to companies—are interested in maximizing their profits. ROA and ROE sometimes are used to gauge the manager s performance. All else equal, managers who make better financial decisions are better able to produce higher ROA and ROE ratios for their organizations. 

In turn, a measure can become a basis for one or several projects when many economic and organizational issues related to their implementation are agreed upon with an investor, state coordinator of work and executors. 

Criterion 1. Investors asks three sets of questions. The first set is concerned with present performance and how it compares with recent past performance. Is the company making money and paying a dividend Is the price of the stock rising Does the company have a good net income as measured by profit per dollar of sales, profit per dollar of investor s equity, and profit per dollar of owner s equity plus long-term debt ... 

Criterion 2. Lenders ask the same questions as investors. In addition, lenders are particularly concerned about the company s ability to repay its debt on time—with interest. Lenders are most interested in short-term cash positions, or liquidity, as measured by the ratio of current assets to current liabilities. They are also concerned with the ratio of cash flow (net income after taxes plus depreciation) to interest on debts. 

The lower capital cost figures for various conservation measures (relative to the investment needed for new energy supplies) provide only a rough indication that such measures will yield attractive economic returns to the investor. Detailed payback calculations, similar to those discussed later for waste heat recovery equipment, are needed to establish economic feasibility in each specific case. 

The full cost of bringing a new drug to market can be thought of as the minimal payoff required from the drugs that successfully reach the market required to induce investors to lay out the money at each step of the way. To measure the full cost of past R D projects, all outlays required to achieve the successes must be compounded (or capitalized) to their present value on the day of market approval at an interest rate equal to the cost of capital. 

A completely accurate measurement of capitalized cost would require the analyst to know, for each dollar spent on the particular sample of NCEs studied by DiMasi, the cost of capital that pertained to that investment at the time it was made. Even though these are retrospective studies, the cost of capital that should be assigned is the cost the investors actually faced at the time they made their investments. 

The issue for this section is how to measure the net cash flows from the point of market approval to the end of the product s life cycle, taking account of the fact that revenues are uncertain, that costs must be incurred to manufacture, market and distribute the products, and that income delayed is worth less to investors than income today. Once the net income from the sale of successful drugs over their lifetime is appropriately measured, it must be compared with the fully capitalized cost of the R D spent to bring them to market. 

By the year 2000, Iran was able to offer about 20 projects in gas and oil sector to investors. These included measures for development of sea deposits and for finishing the modernization of a number of refineries (for example, on an island Lavan). In March of 1998, Bow Valley Energy (Canada) and British Premier Oil signed a contract for 270 millions dollars for providing development of a sea oil field called Balal valued at an estimated 80 millions barrels of petroleum. But... 

---